Observational studyBlood2017
An endpoint associated with clinical benefit after initial treatment of chronic graft-versus-host disease.
Observational study in Blood, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00637689 (Improving Outcomes Assessment in Chronic GVHD), which is not on this map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Improving Outcomes Assessment in Chronic GVHD
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.
- Mesenchymal stromal cells for the prophylaxis and treatment of graft-versus-host disease-a meta-analysis.Stem cell research & therapy · 2020Pooled it
- Treatment of newly diagnosed moderate or severe chronic graft-versus-host disease with prednisone and everolimus (PredEver first): a prospective multicenter phase IIA study.Bone marrow transplantation · 2024Trial
- Axatilimab for Chronic Graft-Versus-Host Disease After Failure of at Least Two Prior Systemic Therapies: Results of a Phase I/II Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Trial
- Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Trial
- A phase 2 multicenter trial of ofatumumab and prednisone as initial therapy for chronic graft-versus-host disease.Blood advances · 2022Trial
- ROCK2 Inhibition With Belumosudil (KD025) for the Treatment of Chronic Graft-Versus-Host Disease.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021Trial
- Randomized controlled study of ECP with methoxsalen as first-line treatment of patients with moderate to severe cGVHD.Blood advances · 2019Trial
- Longitudinal follow-up of response status and concomitant immunosuppression in patients treated with extracorporeal photopheresis for chronic graft versus host disease.Bone marrow transplantation · 2019Trial
- A phase II/III randomized, multicenter trial of prednisone/sirolimusHaematologica · 2018Trial
- Early software-assisted response predicts survival in a prospective cohort of 258 newly diagnosed cGvHD patients.Bone marrow transplantation · 2026Observational
- Advances in treatment of chronic graft-versus-host disease.International journal of hematology · 2026Review
- Belumosudil combination therapy for chronic graft-versus-host-disease in real-world clinical practice.Bone marrow transplantation · 2025Article
- Review
- Establishment and validation of a prognostic model for nasopharyngeal carcinoma patients based on partial response rates.Frontiers in oncology · 2025Article
- Review
- Survival impact of response within the first year in a multicenter prospective observational study of chronic GVHD in a Japanese cohort.International journal of hematology · 2024Observational
- Chronic GVHD: review advances in prevention, novel endpoints, and targeted strategies.Hematology. American Society of Hematology. Education Program · 2023Article
- Telemedicine in Hematopoietic Cell Transplantation and Chimeric Antigen Receptor-T Cell Therapy.Cancers · 2023Review
- A cost-effectiveness analysis of ruxolitinib versus best alternative therapy for patients with steroid-refractory chronic graft-versus-host disease aged > 12 years in Singapore.Cost effectiveness and resource allocation : C/E · 2023Article
- Population-based real-world registry study to evaluate clinical outcomes of chronic graft-versus-host disease.PloS one · 2023Article
Corrections and comments
- Commented on by
Authors and funding
12 authors at 8 institutions in 1 country.
Funding
Abstract
No gold standard has been established as a primary endpoint in trials of initial treatment of chronic graft-versus-host disease (GVHD), and evidence showing the association of any proposed primary endpoint with clinical benefit has not been conclusively demonstrated. To address this gap, we analyzed outcomes in a cohort of 328 patients enrolled in a prospective, multicenter, observational study within 3 months after diagnosis of chronic GVHD. Complete and partial response, stable disease, and progressive disease were defined according to the 2014 National Institutes of Health Consensus Development Conference on Criteria for Clinical Trials in Chronic Graft-Versus-Host Disease. Success was defined as complete or partial response with no secondary systemic treatment or recurrent malignancy at 1 year after enrollment. Success was observed in fewer than 20% of the patients. The burden of disease manifestations at 1 year was lower for patients in this category than for those with stable or progressive disease. Systemic treatment ended earlier, and subsequent mortality was lower among patients with complete or partial response than among those with stable or progressive disease and those who had received secondary systemic treatment. We conclude that survival with a complete or partial response and no previous secondary systemic treatment or recurrent malignancy at 1 year after initial systemic therapy is associated with clinical benefit, a critical characteristic for consideration as a primary endpoint in a pivotal clinical trial. This prospective observational study was registered at www.clinicaltrials.gov as #NCT00637689.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.